Phase 2b Trial Reveals Investigational Oral Therapy PrimeC Slows ALS Progression and Reduces Complication Risk by 64 Percent

New PARADIGM study results show PrimeC is safe and reduces ALS-related complications by 64%. Researchers prepare for Phase 3 trials following functional gains.

By: AXL Media

Published: Mar 17, 2026, 4:20 AM EDT

Source: Information for this report was sourced from Mass General Brigham

A Multi-Targeted Approach to Neurodegeneration

The battle against Amyotrophic Lateral Sclerosis (ALS), a progressive and typically fatal neurodegenerative disease, has seen a significant breakthrough with the results of the PARADIGM phase 2b trial. Researchers at the Mass General Brigham Neuroscience Institute and Barrow Neurological Institute have successfully evaluated PrimeC, an investigational oral therapy that combines the medications celecoxib and ciprofloxacin. Unlike traditional treatments that focus on a single pathway, PrimeC is engineered to simultaneously target neuroinflammation, iron accumulation, and abnormal microRNA activity. This multi-pronged strategy aims to preserve motor neurons and mitigate the muscle weakness that characterizes the disease's advancement.

Safety Profile and Participant Tolerance

The randomized, multicenter trial involved 68 participants who were monitored over a six-month double-blind period, followed by a year-long open-label extension. While drug-related adverse events were more frequent in the PrimeC group compared to the placebo group—20.0 percent versus 4.3 percent—the research team reported that the majority of these events were mild to moderate and temporary in nature. These findings suggest that PrimeC is well-tolerated by patients, clearing a critical hurdle for its continued development and eventual use in broader clinical settings where patient safety is the primary concern.

Functional Gains in Speech and Swallowing

Though the study was primarily designed to assess safety, the functional outcomes recorded in the PrimeC arm were notably superior to those in the placebo group. Using the ALS Functional Rating Scale Revised, researchers observed that patients receiving the investigational therapy had significantly better scores, particularly in the critical categories of speech and swallowing. By the 18-month mark, patients who had been on PrimeC since the beginning of the trial scored nearly eight points higher on average than those who started treatment later. This data suggests that the drug may have a cumulative benefit, preserving essential daily functions for a longer duration than currently available options.